Today: 19 April 2026
Subscribe
Browse Category

LSE:GLEN.L 13 December 2025 - 18 January 2026

Glencore share price: GLEN.L in focus as China hurdles shadow Rio Tinto deal talk

Glencore share price: GLEN.L in focus as China hurdles shadow Rio Tinto deal talk

Glencore shares opened cautiously after a Reuters report said any Rio Tinto deal may require asset sales to satisfy Chinese regulators, with copper and iron ore flagged as key issues. Glencore closed Thursday at 491.0 pence, up 1.4%. Rio Tinto faces a Feb. 5 deadline to make a firm offer or walk away. Societe Generale disclosed a 1.60% long and 1.16% short position in Glencore as of Jan. 14.
16 January 2026
··
Rio Tinto stock price in focus: China approval risk hangs over Glencore talks

Rio Tinto stock price in focus: China approval risk hangs over Glencore talks

Rio Tinto shares closed at 6,468 pence Thursday, up 1.78%, after a volatile session. Analysts warn China may require asset sales for any Rio-Glencore merger, citing concerns over copper market share. Rio announced a two-year copper supply deal with Amazon and signed a new collaboration plan with BHP on Pilbara iron ore. BlackRock disclosed stakes in Rio under UK takeover rules.
16 January 2026
····
Glencore stock swings back into view as Rio deal doubts hit before London open

Glencore stock swings back into view as Rio deal doubts hit before London open

Glencore shares rose nearly 3% to 484.2 pence Wednesday as copper prices surged and merger speculation swirled. A major Australian investor warned Rio Tinto faces “a lot of questions” over any Glencore deal. Rio has until Feb. 5 to make a formal offer or withdraw under UK takeover rules. Talks remain preliminary, with valuation and shareholder approval in focus.
15 January 2026
···
Rio Tinto plc stock edges up as Glencore deal talk deepens with bank advisers lined up

Rio Tinto plc stock edges up as Glencore deal talk deepens with bank advisers lined up

Rio Tinto shares rose 0.3% to 6,231 pence after reports it hired JPMorgan, Evercore, and Macquarie to advise on a possible Glencore takeover. The potential deal could create a $200 billion mining group. Rio has until Feb. 5 to make a formal offer or withdraw, and said there’s no guarantee a bid will happen. BHP is not planning a rival bid, according to sources.
14 January 2026
···
Glencore plc Stock (GLEN.L) News and Forecast: Copper Near $12,000, Cobalt Quotas, UBS Downgrade, and Key 2026 Dates to Watch

Glencore plc Stock (GLEN.L) News and Forecast: Copper Near $12,000, Cobalt Quotas, UBS Downgrade, and Key 2026 Dates to Watch

Glencore shares closed near 375.5p on Friday after volatile trading, as copper prices approached $12,000 per ton and the company trimmed near-term copper guidance. Congo’s cobalt exports have resumed, while UBS downgraded the stock on valuation. Broker targets remain in the low- to mid-400p range. Glencore projects copper output could reach 1 million tonnes by 2028.
13 December 2025
···
1 2

Stock Market Today

  • Nordea Bank Abp's Mixed Share Performance and Valuation Analysis
    April 18, 2026, 10:42 PM EDT. Nordea Bank Abp (HLSE:NDA FI) exhibits mixed returns with a negative year-to-date but a 51.1% total return over one year, showing strong long-term momentum. The bank's share price closed at €16.02, slightly below the €16.55 analyst target and a fair value estimate of €17.03, suggesting it may be undervalued. Nordea is investing heavily in digital technologies and cybersecurity, aiming to improve net margins and fee income. However, potential risks include Nordic housing market weakness and rising regulatory costs. Investors are advised to weigh both upside potential and downside risks before making decisions, considering broader financial sector comparisons and market conditions.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop